Tardive dyskinesia (syndrome): Current concept and modern approaches to its management

Psychiatry and Clinical Neurosciences

Volumn 69, Issue 6, 2015, Pages 321-334

  Lerner, Paul P ^a   Miodownik, Chanoch ^b   Lerner, Vladimir ^b  

^a BAR ILAN UNIVERSITY   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

first generation agents; management; schizophrenia; second generation agents; tardive dyskinesia

Indexed keywords

ALPHA TOCOPHEROL; AMANTADINE; AMMONIA; BRANCHED CHAIN AMINO ACID; CLONAZEPAM; ETIRACETAM; GINKGO BILOBA EXTRACT; HALOPERIDOL; HERBACEOUS AGENT; ICOSAPENTAENOIC ACID; MELATONIN; NEUROLEPTIC AGENT; OMEGA 3 FATTY ACID; PIRACETAM; PLACEBO; PROPRANOLOL; PYRIDOXINE; RESVERATROL; TETRABENAZINE; UNCLASSIFIED DRUG; YI GAN SAN; ZONISAMIDE; ADRENERGIC RECEPTOR AFFECTING AGENT; ANTICONVULSIVE AGENT; ANTIOXIDANT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; ISOLEUCINE; ISOXAZOLE DERIVATIVE; LEUCINE; NOOTROPIC AGENT; PLANT EXTRACT; STILBENE DERIVATIVE; VALINE; VITAMIN; YI-GAN SAN;

ABNORMAL INVOLUNTARY MOVEMENT SCALE; ADD ON THERAPY; AKATHISIA; ANGINA PECTORIS; ATAXIA; BEHAVIOR DISORDER; BIPOLAR DISORDER; CHOREA; CHOREOATHETOSIS; CONCENTRATION LOSS; DEPRESSION; DIZZINESS; DROWSINESS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DYSARTHRIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FLUSHING; GENETIC PREDISPOSITION; HEADACHE; HEART ARRHYTHMIA; HEMIBALLISM; HUMAN; HUNTINGTON CHOREA; HYPERKINESIA; HYPERTENSION; INCIDENCE; INFANTILE SPASM; INSOMNIA; INTRAHEPATIC CHOLESTASIS; IRRITABILITY; LEUKOPENIA; LOSS OF APPETITE; MOTOR DYSFUNCTION; MYOCLONUS SEIZURE; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; OROFACIAL DYSKINESIA; PARKINSONISM; PATHOPHYSIOLOGY; PREVALENCE; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SEIZURE; SOMNOLENCE; SUICIDAL IDEATION; TARDIVE DYSKINESIA; THROMBOCYTOPENIA; THROMBOPHLEBITIS; TONIC CLONIC SEIZURE; UNSPECIFIED SIDE EFFECT; ANALOGS AND DERIVATIVES; GINKGO BILOBA; MOVEMENT DISORDERS;

ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC UPTAKE INHIBITORS; ALPHA-TOCOPHEROL; AMANTADINE; ANTICONVULSANTS; ANTIOXIDANTS; ANTIPSYCHOTIC AGENTS; CLONAZEPAM; DOPAMINE AGENTS; DRUGS, CHINESE HERBAL; FATTY ACIDS, OMEGA-3; GINKGO BILOBA; HUMANS; ISOLEUCINE; ISOXAZOLES; LEUCINE; MELATONIN; MOVEMENT DISORDERS; NOOTROPIC AGENTS; PIRACETAM; PLANT EXTRACTS; PROPRANOLOL; PYRIDOXINE; STILBENES; TETRABENAZINE; VALINE; VITAMINS;

EID: 84930377530     PISSN: 13231316     EISSN: 14401819     Source Type: Journal    
DOI: 10.1111/pcn.12270     Document Type: Review

References (138)

1. Schonecker M,. [Paroxysmal dyskinesia as the effect of megaphen]. Nervenarzt 1957; 28: 550-553.
2. Faurbye A, Rasch PJ, Petersen PB, Brandborg G, Pakkenberg H,. Neurological symptoms in pharmacotherapy of psychoses. Acta Psychiatr. Scand. 1964; 40: 10-27.
3. Fenton WS,. Prevalence of spontaneous dyskinesia in schizophrenia. J. Clin. Psychiatry 2000; 61 (Suppl. 4): 10-14.
4. Bhidayasiri R, Boonyawairoj S,. Spectrum of tardive syndromes: Clinical recognition and management. Postgrad. Med. J. 2011; 87: 132-141.
5. Lerner V, Miodownik C,. Motor symptoms of schizophrenia: Is tardive dyskinesia a symptom or side effect? A modern treatment. Curr. Psychiatry Rep. 2011; 13: 295-304.
6. Browne S, Roe M, Lane A, et al. Quality of life in schizophrenia: Relationship to sociodemographic factors, symptomatology and tardive dyskinesia. Acta Psychiatr. Scand. 1996; 94: 118-124.
7. Ballesteros J, Gonzalez-Pinto A, Bulbena A,. Tardive dyskinesia associated with higher mortality in psychiatric patients: Results of a meta-analysis of seven independent studies. J. Clin. Psychopharmacol. 2000; 20: 188-194.
8. Youssef HA, Waddington JL,. Morbidity and mortality in tardive dyskinesia: Associations in chronic schizophrenia. Acta Psychiatr. Scand. 1987; 75: 74-77.
9. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th edn. American Psychiatric Association, Washington, DC, 2013.
10. Li CR, Chung YC, Park TW, et al. Clozapine-induced tardive dyskinesia in schizophrenic patients taking clozapine as a first-line antipsychotic drug. World J. Biol. Psychiatry 2009; 10: 919-924.
11. Molho ES, Factor SA,. Possible tardive dystonia resulting from clozapine therapy. Mov. Disord. 1999; 14: 873-874.
12. Duggal HS, Mendhekar DN,. Clozapine-induced tardive dystonia (blepharospasm). J. Neuropsychiatry Clin. Neurosci. 2007; 19: 86-87.
13. Mendhekar DN, Duggal HS,. Clozapine-induced tardive dyskinesia and hypothyroidism. J. Neuropsychiatry Clin. Neurosci. 2006; 18: 245-246.
14. Orti-Pareja M, Jimenez-Jimenez FJ, Vazquez A, et al. Drug-induced tardive syndromes. Parkinsonism Relat. Disord. 1999; 5: 59-65.
15. Klawans H Jr, Ilahi MM, Shenker D,. Theoretical implications of the use of L-dopa in parkinsonism. A review. Acta Neurol. Scand. 1970; 46: 409-441.
16. Kulkarni SK, Naidu PS,. Pathophysiology and drug therapy of tardive dyskinesia: Current concepts and future perspectives. Drugs Today (Barc.) 2003; 39: 19-49.
17. Bishnoi M, Chopra K, Kulkarni SK,. Possible anti-oxidant and neuroprotective mechanisms of zolpidem in attenuating typical anti-psychotic-induced orofacial dyskinesia: A biochemical and neurochemical study. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007; 31: 1130-1138.
18. Elkashef AM, Wyatt RJ,. Tardive dyskinesia: Possible involvement of free radicals and treatment with vitamin E. Schizophr. Bull. 1999; 25: 731-740.
19. Jeste DV, Lohr JB, Kaufmann CA, Wyatt RJ,. Pathophysiology of tardive dyskinesia: Evaluation of supersensitivity theory and alternative hypotheses. In:, Casey DE, Gardos G, (eds). Tardive Dyskinesia and Neuroleptics: From Dogma to Reason. American Psychiatric Press, Washington, DC, 1986; 15-32.
20. Lohr JB, Kuczenski R, Niculescu AB,. Oxidative mechanisms and tardive dyskinesia. CNS Drugs 2003; 17: 47-62.
21. Miller R, Chouinard G,. Loss of striatal cholinergic neurons as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia. Biol. Psychiatry 1993; 34: 713-738.
22. Vaddadi K, Hakansson K, Clifford J, Waddington J,. Tardive dyskinesia and essential fatty acids. Int. Rev. Psychiatry 2006; 18: 133-143.
23. Lerner V, Miodownik C, Kaptsan A, et al. Vitamin B6 treatment for tardive dyskinesia: A randomized, double-blind, placebo-controlled, crossover study. J. Clin. Psychiatry 2007; 68: 1648-1654.
24. Libov I, Miodownik C, Bersudsky Y, Dwolatzky T, Lerner V,. Efficacy of piracetam in the treatment of tardive dyskinesia in schizophrenic patients: A randomized, double-blind, placebo-controlled crossover study. J. Clin. Psychiatry 2007; 68: 1031-1037.
25. Tan YL, Zhou DF, Zhang XY,. Decreased plasma brain-derived neurotrophic factor levels in schizophrenic patients with tardive dyskinesia: Association with dyskinetic movements. Schizophr. Res. 2005; 74: 263-270.
26. Lencz T, Malhotra AK,. Pharmacogenetics of antipsychotic-induced side effects. Dialogues Clin. Neurosci. 2009; 11: 405-415.
27. Liou YJ, Wang YC, Chen JY, et al. Association analysis of polymorphisms in the N-methyl-D-aspartate (NMDA) receptor subunit 2B (GRIN2B) gene and tardive dyskinesia in schizophrenia. Psychiatry Res. 2007; 153: 271-275.
28. Rizos EN, Siafakas N, Katsantoni E, et al. Association of the dopamine D3 receptor Ser9Gly and of the serotonin 2C receptor gene polymorphisms with tardive dyskinesia in Greeks with chronic schizophrenic disorder. Psychiatr. Genet. 2009; 19: 106-107.
29. Souza RP, Remington G, Chowdhury NI, et al. Association study of the GSK-3B gene with tardive dyskinesia in European Caucasians. Eur. Neuropsychopharmacol. 2010; 20: 688-694.
30. Kane JM, Smith JM,. Tardive dyskinesia: Prevalence and risk factors, 1959 to 1979. Arch. Gen. Psychiatry 1982; 39: 473-481.
31. Yassa R, Jeste DV,. Gender differences in tardive dyskinesia: A critical review of the literature. Schizophr. Bull. 1992; 18: 701-715.
32. Kane JM, Woerner M, Lieberman J,. Tardive dyskinesia: Prevalence, incidence, and risk factors. J. Clin. Psychopharmacol. 1988; 8: 52S-56S.
33. Chakos MH, Alvir JM, Woerner MG, et al. Incidence and correlates of tardive dyskinesia in first episode of schizophrenia. Arch. Gen. Psychiatry 1996; 53: 313-319.
34. Glazer WM, Morgenstern H, Doucette JT,. Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications. J. Clin. Psychiatry 1993; 54: 133-139.
35. Woerner MG, Alvir JM, Saltz BL, Lieberman JA, Kane JM,. Prospective study of tardive dyskinesia in the elderly: Rates and risk factors. Am. J. Psychiatry 1998; 155: 1521-1528.
36. Jeste DV, Caligiuri MP, Paulsen JS, et al. Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients. Arch. Gen. Psychiatry 1995; 52: 756-765.
37. Caroff SN, Mann SC, Campbell EC, Sullivan KA,. Movement disorders associated with atypical antipsychotic drugs. J. Clin. Psychiatry 2002; 63 (Suppl. 4): 12-19.
38. Correll CU, Leucht S, Kane JM,. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: A systematic review of 1-year studies. Am. J. Psychiatry 2004; 161: 414-425.
39. Gebhardt S, Hartling F, Hanke M, et al. Prevalence of movement disorders in adolescent patients with schizophrenia and in relationship to predominantly atypical antipsychotic treatment. Eur. Child Adolesc. Psychiatry 2006; 15: 371-382.
40. Glazer WM,. Review of incidence studies of tardive dyskinesia associated with typical antipsychotics. J. Clin. Psychiatry 2000; 61 (Suppl. 4): 15-20.
41. Glazer WM,. Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. J. Clin. Psychiatry 2000; 61 (Suppl. 3): 16-21.
42. Kane JM,. Tardive dyskinesia rates with atypical antipsychotics in adults: Prevalence and incidence. J. Clin. Psychiatry 2004; 65 (Suppl. 9): 16-20.
43. Marder SR, Meibach RC,. Risperidone in the treatment of schizophrenia. Am. J. Psychiatry 1994; 151: 825-835.
44. Margolese HC, Chouinard G, Kolivakis TT, Beauclair L, Miller R, Annable L,. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia. Can. J. Psychiatry 2005; 50: 703-714.
45. de Leon J,. The effect of atypical versus typical antipsychotics on tardive dyskinesia: A naturalistic study. Eur. Arch. Psychiatry Clin. Neurosci. 2007; 257: 169-172.
46. Tenback DE, van Harten PN, Slooff CJ, van Os J,. Incidence and persistence of tardive dyskinesia and extrapyramidal symptoms in schizophrenia. J. Psychopharmacol. 2010; 24: 1031-1035.
47. Woods SW, Morgenstern H, Saksa JR, et al. Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: A prospective cohort study. J. Clin. Psychiatry 2010; 71: 463-474.
48. Correll CU, Schenk EM,. Tardive dyskinesia and new antipsychotics. Curr. Opin. Psychiatry 2008; 21: 151-156.
49. Geddes J, Freemantle N, Harrison P, Bebbington P,. Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression analysis. BMJ 2000; 321: 1371-1376.
50. Peluso MJ, Lewis SW, Barnes TR, Jones PB,. Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs. Br. J. Psychiatry 2012; 200: 387-392.
51. Soares KV, McGrath JJ,. The treatment of tardive dyskinesia-a systematic review and meta-analysis. Schizophr. Res. 1999; 39: 1-16.
52. Allen RM,. Palliative treatment of tardive dyskinesia with combination of amantadine-neuroleptic administration. Biol. Psychiatry 1982; 17: 719-727.
53. Decker BL, Davis JM, Jonowsky DS, el-Yousef MK, Sekerke HJ,. Amantadine hydrochloride treatment of tardive dyskinesia. N. Engl. J. Med. 1971; 285: 860.
54. Vale S, Espejel MA,. Amantadine for dyskinesia tarda. N. Engl. J. Med. 1971; 284: 673.
55. Crane GE,. More on amantadine in tardive dyskinesia. N. Engl. J. Med. 1971; 285: 1150-1151.
56. Merren MD,. Amantadine in tardive dyskinesia. N. Engl. J. Med. 1972; 286: 268.
57. Angus S, Sugars J, Boltezar R, Koskewich S, Schneider NM,. A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia. J. Clin. Psychopharmacol. 1997; 17: 88-91.
58. Pappa S, Tsouli S, Apostolou G, Mavreas V, Konitsiotis S,. Effects of amantadine on tardive dyskinesia: A randomized, double-blind, placebo-controlled study. Clin. Neuropharmacol. 2010; 33: 271-275.
59. Howland RH,. Drug therapies for tardive dyskinesia: Part 1. J. Psychosoc. Nurs. Ment. Health Serv. 2011; 49: 13-16.
60. Barnes TR, Kidger T,. Clonazepam and tardive dyskinesia. Am. J. Psychiatry 1981; 138: 1127-1128.
61. Bobruff A, Gardos G, Tarsy D, Rapkin RM, Cole JO, Moore P,. Clonazepam and phenobarbital in tardive dyskinesia. Am. J. Psychiatry 1981; 138: 189-193.
62. Sedman G,. Clonazepam in treatment of tardive oral dyskinesia [letter]. Br. Med. J. 1976; 2: 583.
63. Thaker GK, Nguyen JA, Strauss ME, Jacobson R, Kaup BA, Tamminga CA,. Clonazepam treatment of tardive dyskinesia: A practical GABAmimetic strategy. Am. J. Psychiatry 1990; 147: 445-451.
64. Perenyi A, Farkas A,. Propranolol in the treatment of tardive dyskinesia. Biol. Psychiatry 1983; 18: 391-394.
65. Chaudhry R, Radonjic D, Waters B,. Efficacy of propranolol in a patient with tardive dyskinesia and extrapyramidal syndrome. Am. J. Psychiatry 1982; 139: 674-676.
66. Bacher NM, Lewis HA,. Low-dose propranolol in tardive dyskinesia. Am. J. Psychiatry 1980; 137: 495-497.
67. Schrodt GR Jr, Wright JH, Simpson R, Moore DP, Chase S,. Treatment of tardive dyskinesia with propranolol. J. Clin. Psychiatry 1982; 43: 328-331.
68. Silver JM, Yudofsky SC, Kogan M, Katz BL,. Elevation of thioridazine plasma levels by propranolol. Am. J. Psychiatry 1986; 143: 1290-1292.
69. Vestal RE, Kornhauser DM, Hollifield JW, Shand DG,. Inhibition of propranolol metabolism by chlorpromazine. Clin. Pharmacol. Ther. 1979; 25: 19-24.
70. Factor SA,. Propranolol therapy for tardive dyskinesia revisited. Mov. Disord. 2012; 27: 1703.
71. Guay DR,. Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders. Am. J. Geriatr. Pharmacother. 2010; 8: 331-373.
72. Chen JJ, Ondo WG, Dashtipour K, Swope DM,. Tetrabenazine for the treatment of hyperkinetic movement disorders: A review of the literature. Clin. Ther. 2012; 34: 1487-1504.
73. Kazamatsuri H, Chien C, Cole JO,. Treatment of tardive dyskinesia. I. Clinical efficacy of a dopamine-depleting agent, tetrabenazine. Arch. Gen. Psychiatry 1972; 27: 95-99.
74. Jankovic J,. Treatment of hyperkinetic movement disorders with tetrabenazine: A double-blind crossover study. Ann. Neurol. 1982; 11: 41-47.
75. Ondo WG, Hanna PA, Jankovic J,. Tetrabenazine treatment for tardive dyskinesia: Assessment by randomized videotape protocol. Am. J. Psychiatry 1999; 156: 1279-1281.
76. Kenney C, Hunter C, Jankovic J,. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov. Disord. 2007; 22: 193-197.
77. LeWitt PA,. Tardive dyskinesia caused by tetrabenazine. Clin. Neuropharmacol. 2013; 36: 92-93.
78. Cloud LJ, Zutshi D, Factor SA,. Tardive dyskinesia: Therapeutic options for an increasingly common disorder. Neurother. 2014; 11: 166-176.
79. Rana AQ, Chaudry ZM, Blanchet PJ,. New and emerging treatments for symptomatic tardive dyskinesia. Drug Des. Devel. Ther. 2013; 7: 1329-1340.
80. Richardson MA, Bevans ML, Weber JB, et al. Branched chain amino acids decrease tardive dyskinesia symptoms. Psychopharmacology (Berl) 1999; 143: 358-364.
81. Howland RH,. Drug therapies for tardive dyskinesia: Part 2. J. Psychosoc. Nurs. Ment. Health Serv. 2011; 49: 17-20.
82. Richardson MA, Bevans ML, Read LL, et al. Efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men. Am. J. Psychiatry 2003; 160: 1117-1124.
83. Richardson MA, Small AM, Read LL, Chao HM, Clelland JD,. Branched chain amino acid treatment of tardive dyskinesia in children and adolescents. J. Clin. Psychiatry 2004; 65: 92-96.
84. Richardson MA, Bevans M, Weber J, Gonzalez J, Flynn CJ, Amira L,. Tardive dyskinesia: A nutritional intervention. Eighth Ann New York State Office of Mental Health Research Conference. Albany, New York: NYS Office of Mental Health; 1995: 25.
85. Doo AR, Kim SN, Park JY, et al. Neuroprotective effects of an herbal medicine, Yi-Gan San on MPP+/MPTP-induced cytotoxicity in vitro and in vivo. J. Ethnopharmacol. 2010; 131: 433-442.
86. Miyaoka T, Furuya M, Yasuda H, et al. Yi-gan san for the treatment of neuroleptic-induced tardive dyskinesia: An open-label study. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008; 32: 761-764.
87. Murata M, Hasegawa K, Kanazawa I, Japan Zonisamide on PDSG. Zonisamide improves motor function in Parkinson disease: A randomized, double-blind study. Neurology 2007; 68: 45-50.
88. Iwata Y, Irie S, Uchida H, et al. Effects of zonisamide on tardive dyskinesia: A preliminary open-label trial. J. Neurol. Sci. 2012; 315: 137-140.
89. Bastianetto S, Zheng WH, Quirion R,. The Ginkgo biloba extract (EGb 761) protects and rescues hippocampal cells against nitric oxide-induced toxicity: Involvement of its flavonoid constituents and protein kinase C. J. Neurochem. 2000; 74: 2268-2277.
90. DeFeudis FV, Drieu K,. Ginkgo biloba extract (EGb 761) and CNS functions: Basic studies and clinical applications. Curr. Drug Targets 2000; 1: 25-58.
91. Zhang XY, Zhou DF, Zhang PY, Wu GY, Su JM, Cao LY,. A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia. J. Clin. Psychiatry 2001; 62: 878-883.
92. Zhang WF, Tan YL, Zhang XY, Chan RC, Wu HR, Zhou DF,. Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: A randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 2011; 72: 615-621.
93. Zhang XY, Zhang WF, Zhou DF, et al. Brain-derived neurotrophic factor levels and its Val66Met gene polymorphism predict tardive dyskinesia treatment response to Ginkgo biloba. Biol. Psychiatry 2012; 72: 700-706.
94. Sirsi D, Safdieh JE,. The safety of levetiracetam. Expert Opin. Drug Saf. 2007; 6: 241-250.
95. McGavin CL, John V, Musser WS,. Levetiracetam as a treatment for tardive dyskinesia: A case report. Neurology 2003; 61: 419.
96. Bona JR,. Treatment of neuroleptic-induced tardive dyskinesia with levetiracetam: A case series. J. Clin. Psychopharmacol. 2006; 26: 215-216.
97. Konitsiotis S, Pappa S, Mantas C, Mavreas V,. Levetiracetam in tardive dyskinesia: An open label study. Mov. Disord. 2006; 21: 1219-1221.
98. Meco G, Fabrizio E, Epifanio A, et al. Levetiracetam in tardive dyskinesia. Clin. Neuropharmacol. 2006; 29: 265-268.
99. Zivkovic SA, Costa G, Bond G, Abu-Elmagd KM,. Treatment of tardive dyskinesia with levetiracetam in a transplant patient. Acta Neurol. Scand. 2008; 117: 351-353.
100. Woods SW, Saksa JR, Baker CB, Cohen SJ, Tek C,. Effects of levetiracetam on tardive dyskinesia: A randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry 2008; 69: 546-554.
101. Casey DE,. Pathophysiology of antipsychotic drug-induced movement disorders. J. Clin. Psychiatry 2004; 65 (Suppl. 9): 25-28.
102. Margineanu DG, Klitgaard H,. Inhibition of neuronal hypersynchrony in vitro differentiates levetiracetam from classical antiepileptic drugs. Pharmacol. Res. 2000; 42: 281-285.
103. Schaeffer MC, Cochary EF, Sadowski JA,. Subtle abnormalities of gait detected early in vitamin B6 deficiency in aged and weanling rats with hind leg gait analysis. J. Am. Coll. Nutr. 1990; 9: 120-127.
104. Altun A, Ugur-Altun B,. Melatonin: Therapeutic and clinical utilization. Int. J. Clin. Pract. 2007; 61: 835-845.
105. Reiter RJ, Maestroni GJ,. Melatonin in relation to the antioxidative defense and immune systems: Possible implications for cell and organ transplantation. J. Mol. Med. (Berl.) 1999; 77: 36-39.
106. Shamir E, Barak Y, Plopsky I, Zisapel N, Elizur A, Weizman A,. Is melatonin treatment effective for tardive dyskinesia? J. Clin. Psychiatry 2000; 61: 556-558.
107. Shamir E, Barak Y, Shalman I, et al. Melatonin treatment for tardive dyskinesia: A double-blind, placebo-controlled, crossover study. Arch. Gen. Psychiatry 2001; 58: 1049-1052.
108. Melatonin Natural Medicines Comprehensive Database. 2010. [Cited 14 January 2015.] Available from URL: http://www.nlm.nih.gov/medlineplus/druginfo/natural/940.html.
109. Nelson LA, McGuire JM, Hausafus SN,. Melatonin for the treatment of tardive dyskinesia. Ann. Pharmacother. 2003; 37: 1128-1131.
110. Castro F, Carrizo E, Prieto de Rincon D, et al. Effectiveness of melatonin in tardive dyskinesia. Invest. Clin. 2011; 52: 252-260.
111. Mirnikjoo B, Brown SE, Kim HF, Marangell LB, Sweatt JD, Weeber EJ,. Protein kinase inhibition by omega-3 fatty acids. J. Biol. Chem. 2001; 276: 10888-10896.
112. Ikemoto A, Nitta A, Furukawa S, et al. Dietary n-3 fatty acid deficiency decreases nerve growth factor content in rat hippocampus. Neurosci. Lett. 2000; 285: 99-102.
113. Sarsilmaz M, Songur A, Ozyurt H, et al. Potential role of dietary omega-3 essential fatty acids on some oxidant/antioxidant parameters in rats' corpus striatum. Prostaglandins Leukot. Essent. Fatty Acids 2003; 69: 253-259.
114. Emsley R, Niehaus DJ, Koen L, et al. The effects of eicosapentaenoic acid in tardive dyskinesia: A randomized, placebo-controlled trial. Schizophr. Res. 2006; 84: 112-120.
115. Puri BK,. High-resolution magnetic resonance imaging sinc-interpolation-based subvoxel registration and semi-automated quantitative lateral ventricular morphology employing threshold computation and binary image creation in the study of fatty acid interventions in schizophrenia, depression, chronic fatigue syndrome and Huntington's disease. Int. Rev. Psychiatry 2006; 18: 149-154.
116. Malykh AG, Sadaie MR,. Piracetam and piracetam-like drugs: From basic science to novel clinical applications to CNS disorders. Drugs 2010; 70: 287-312.
117. Winblad B,. Piracetam: A review of pharmacological properties and clinical uses. CNS Drug Rev. 2005; 11: 169-182.
118. Fehr C, Dahmen N, Klawe C, Eicke M, Szegedi A,. Piracetam in the treatment of tardive dyskinesia and akathisia: A case report. J. Clin. Psychopharmacol. 2001; 21: 248-249.
119. Kabes J, Sikora J, Stary O, Pisvejc J, Hanzlicek L,. [Effectiveness of piracetam in tardive dyskinesia-double-blind cross-over controlled trial with a placebo]. Cesk. Psychiatr. 1983; 79: 339-345.
120. Han YS, Bastianetto S, Dumont Y, Quirion R,. Specific plasma membrane binding sites for polyphenols, including resveratrol, in the rat brain. J. Pharmacol. Exp. Ther. 2006; 318: 238-245.
121. Busanello A, Barbosa NB, Peroza LR, et al. Resveratrol protects against a model of vacuous chewing movements induced by reserpine in mice. Behav. Pharmacol. 2011; 22: 71-75.
122. Busanello A, Peroza LR, Wagner C, et al. Resveratrol reduces vacuous chewing movements induced by acute treatment with fluphenazine. Pharmacol. Biochem. Behav. 2012; 101: 307-310.
123. Dakshinamurti K, Paulose CS, Viswanathan M, Siow YL, Sharma SK, Bolster B,. Neurobiology of pyridoxine. Ann. N. Y. Acad. Sci. 1990; 585: 128-144.
124. Dreyfus PM, Geel SE,. Vitamins and nutritional deficiencies. In:, Siegel GJ, Alberts RW, Agranoff BW, Katzman R, (eds). Basic Neurochemistry. Little Brown, Boston, 1981; 661-679.
125. Goodman LS, Gilman A,. The Pharmacologic Basis of Therapeutics, 8th edn. McGraw-Hill, New York, 1992.
126. Viswanathan M, Siow YL, Paulose CS, Dakshinamurti K,. Pineal indoleamine metabolism in pyridoxine-deficient rats. Brain Res. 1988; 473: 37-42.
127. Cabrini L, Bergami R, Fiorentini D, Marchetti M, Landi L, Tolomelli B,. Vitamin B6 deficiency affects antioxidant defences in rat liver and heart. Biochem. Mol. Biol. Int. 1998; 46: 689-697.
128. Miodownik C, Meoded A, Libov I, Bersudsky Y, Sela BA, Lerner V,. Pyridoxal plasma level in schizophrenic and schizoaffective patients with and without tardive dyskinesia. Clin. Neuropharmacol. 2008; 31: 197-203.
129. Lerner V, Miodownik C, Kaptsan A, et al. Vitamin B6 in the treatment of tardive dyskinesia: A double-blind, placebo-controlled, crossover study. Am. J. Psychiatry 2001; 158: 1511-1514.
130. Tarsy D,. Tardive dyskinesia. Curr. Treat. Options Neurol. 2000; 2: 205-214.
131. Adler LA, Edson R, Lavori P, et al. Long-term treatment effects of vitamin E for tardive dyskinesia. Biol. Psychiatry 1998; 43: 868-872.
132. Lohr JB, Caligiuri MP,. A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia. J. Clin. Psychiatry 1996; 57: 167-173.
133. Adler LA, Rotrosen J, Edson R, et al. Vitamin E treatment for tardive dyskinesia. Arch. Gen. Psychiatry 1999; 56: 836-841.
134. Shriqui CL, Bradwejn J, Annable L, Jones BD,. Vitamin E in the treatment of tardive dyskinesia: A double-blind placebo-controlled study. Am. J. Psychiatry 1992; 149: 391-393.
135. Dorevitch A, Kalian M, Shlafman M, Lerner V,. Treatment of long-term tardive dyskinesia with vitamin E. Biol. Psychiatry 1997; 41: 114-116.
136. Boomershine KH, Shelton PS, Boomershine JE,. Vitamin E in the treatment of tardive dyskinesia. Ann. Pharmacother. 1999; 33: 1195-1202.
137. Barak Y, Swartz M, Shamir E, Stein D, Weizman A,. Vitamin E (alpha-tocopherol) in the treatment of tardive dyskinesia: A statistical meta-analysis. Ann. Clin. Psychiatry 1998; 10: 101-105.
138. Soares KV, McGrath JJ,. Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst. Rev. 2001; (4) CD000209.